Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- AWS 5/21: The Beginning of the End for QE
- PFP 5/21: Below the Surface
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SUMMER INFAN | SUMR | 8.43% |
| SCIENTIFIC L | SCIL | 8.00% |
| FEDERAL MOGU | FDML | 6.57% |
| NATUS MEDICA | BABY | 5.62% |
| RADIANT LOGI | RLGT | 5.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Anacor Pharmaceuticals, Inc. ( ANAC - Snapshot Report ) reported fourth-quarter 2012 net loss per share of 36 cents, narrower than the Zacks Consensus Estimate of a loss of 44 cents and the year-ago loss of 52 cents per share.
Fourth-quarter revenues were $3.3 million, compared with $2.6 million in the year-ago quarter. Revenues edged past the Zacks Consensus Estimate of $3 million.
In fourth quarter 2012, research and development expenses fell 13.8% year over year to $12 million. The decrease was driven by lower clinical trial activity of tavaborole. Selling, general and administrative expenses fell 3.7% year over year to $2.8 million in the reported quarter.
In Dec 2012, Anacor Pharma announced the achievement of the second development candidate in its animal health collaboration with Eli Lilly and Company ( LLY - Analyst Report ) . As per the agreement, Anacor Pharma received a payment of $1 million for this milestone. Additionally, the company is eligible to receive development and regulatory milestones as well as tiered royalties.
Full-year 2012 net loss per share was $1.76, narrower than the Zacks Consensus Estimate of a loss of $1.82 but wider than the year-ago loss of $1.71 per share. Revenues in 2012 were $10.7 million, compared with $20.3 million in 2011. Revenues for 2012 narrowly missed the Zacks Consensus Estimate of $11 million.
Pipeline Update
Apart from releasing financial results, Anacor Pharma also provided an update on its pipeline. In the first quarter of 2013, the company announced positive results from two phase III studies on its topical antifungal candidate, tavaborole (AN2690). The studies, 301 and 302, evaluated the candidate for the prevention of onychomycosis. They were conducted under the US Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) program. Anacor Pharma intends to seek US approval for the candidate in the indication in mid-2013.
Moreover, Anacor Pharma expects data from the ongoing phase II dose-ranging study in adolescents for its atopic dermatitis candidate, AN2728, shortly.
Anacor Pharma carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. (LCI ) and QLT Inc. ( QLTI - Snapshot Report ) look more attractive in the pharma space with a Zacks Rank #1 (Strong Buy).
Read the full Analyst Report on LLY
Read the full Snapshot Report on ANAC
Read the full Snapshot Report on QLTI
Read the full Snapshot Report on LCI